

# Antiretroviral therapy and early mortality in South Africa

Andrew Boule,<sup>a</sup> Peter Bock,<sup>b</sup> Meg Osler,<sup>c</sup> Karen Cohen,<sup>d</sup> Liezl Channing,<sup>e</sup> Katherine Hilderbrand,<sup>f</sup> Eula Mothibi,<sup>b</sup> Virginia Zweigenthal,<sup>c</sup> Neviline Slingers,<sup>g</sup> Keith Cloete<sup>c</sup> & Fareed Abdullah<sup>g</sup>

**Objective** To describe province-wide outcomes and temporal trends of the Western Cape Province antiretroviral treatment (ART) programme 5 years since inception, and to demonstrate the utility of the WHO monitoring system for ART.

**Methods** The treatment programme started in 2001 through innovator sites. Rapid scaling-up of ART provision began early in 2004, located predominantly in primary-care facilities. Data on patients starting ART were prospectively captured into facility-based registers, from which monthly cross-sectional activity and quarterly cohort reports were aggregated. Retention in care, mortality, loss to follow-up and laboratory outcomes were calculated at 6-monthly durations on ART.

**Findings** By the end of March 2006, 16 234 patients were in care. The cohort analysis included 12 587 adults and 1709 children. Women accounted for 70% of adults enrolled. After 4 and 3 years on ART respectively, 72.0% of adults (95% confidence interval, CI: 68.0–75.6) and 81.5% (95% CI: 75.7–86.1) of children remained in care. The percentage of adults starting ART with CD4 counts less than 50 cells/ $\mu$ l fell from 51.3% in 2001 to 21.5% in 2005, while mortality at 6 months fell from 12.7% to 6.6%, offset in part by an increase in loss to follow-up (reaching 4.7% at 6 months in 2005). Over 85% of adults tested had viral loads below 400 copies/ml at 6-monthly durations until 4 years on ART.

**Conclusion** The location of care in primary-care sites in this programme was associated with good retention in care, while the scaling-up of ART provision was associated with reduced early mortality.

Bulletin of the World Health Organization 2008;86:678–687.

Une traduction en français de ce résumé figure à la fin de l'article. Al final del artículo se facilita una traducción al español. الترجمة العربية لهذه الخلاصة في نهاية النص الكامل لهذه المقالة.

## Introduction

The national antiretroviral treatment (ART) programme in South Africa was launched in April 2004.<sup>1</sup> However, for some years prior to this, demonstration projects had provided ART to HIV-infected individuals with advanced disease through government health services. Several projects were located in the Western Cape Province which, as a result, is able to report on outcomes up to 4 years after initiation of therapy. The first such project began providing ART in Khayelitsha in May 2001,<sup>2,3</sup> followed by a project in Gugulethu in September 2002.<sup>4–6</sup>

Since inception, the clinical guidelines and approaches to monitoring used in the Western Cape Province have been in line with those recommended by WHO.<sup>7–9</sup> The treatment setting is reflective of public sector health services

in South Africa. A description of outcomes 5 years into this provincial programme, and after significant scaling-up of care, has relevance to what can be anticipated in South Africa and other similar settings in the region.

This paper demonstrates that robust and useful information can be generated using a basics-first, paper-based monitoring system, as recommended by WHO.<sup>10</sup> There are some sites in the province that collect clinical data electronically and enhance these data for cohort surveillance and research. These are designated as sentinel sites and address particular clinical and epidemiological questions. This takes pressure off the remaining sites from having to institute complex monitoring systems and ensures that in the majority of sites only the information essential for management and programme assessment is collected.

The aim of this paper is to describe the key clinical outcomes in the Western Cape provincial ART programme, in patients on therapy for up to 4 years, and the evolution of the programme over a 5-year period. Secondary aims are to demonstrate the field utility of the WHO monitoring guidelines and the feasibility of scaling-up services through primary-care sites.

## Programme description

The first project to routinely offer ART in the public sector and on a district-wide basis in South Africa was started in 2001 as a partnership between the provincial government and Médecins Sans Frontières in the Cape Town township of Khayelitsha. At that time, several local clinicians had already been involved in ART provision through clinical studies and private funding and

<sup>a</sup> School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

<sup>b</sup> Absolute Return for Kids, Cape Town, South Africa.

<sup>c</sup> Department of Health, Provincial Government of the Western Cape, Cape Town, South Africa.

<sup>d</sup> Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.

<sup>e</sup> The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.

<sup>f</sup> Médecins Sans Frontières, Cape Town, South Africa.


<sup>g</sup> International HIV/AIDS Alliance, Brighton, England.

Correspondence to Andrew Boule (e-mail: andrew.boule@uct.ac.za).

doi:10.2471/BLT.07.045294

(Submitted: 25 June 2007 – Revised version received: 17 October 2007 – Accepted: 27 November 2007 – Published online: 6 May 2008)

Fig. 1. Trends in enrolment of patients on ART




ART, antiretroviral therapy.

were able to support this and subsequent initiatives. These early sites can be considered as “innovator sites” in as far as they were able to grapple with many of the logistics of setting up services in anticipation of a more rapid scaling-up of ART services. By the time the national programme was launched in South Africa in April 2004, there were 16 discrete sites offering ART in the province, eight of which were in primary care. At this time there were 2327 patients receiving ART. By the end of March 2006, there were 16 234 patients receiving ART (87%

adults) across 43 sites, the majority being treated in primary-care settings (67% in clinics and community health centres, and 13% in district hospitals). Enrolment increased steadily over this time to reach 1000 patients per month, with seasonal decreases in enrolment each December (Fig. 1 and Fig. 2). Care was first offered as part of the primary-care HIV intervention for children in 2002, with follow-up for children in this analysis extending to 3 years. Children were defined as patients starting ART under the age of 14 years.


Patients were considered eligible for ART if they had a stage IV illness (excluding extrapulmonary tuberculosis) or a CD4 count less than 200 cells/µl. The adult regimens used throughout comprised two nucleotide reverse transcriptase inhibitors (NRTIs) and one non-nucleotide reverse transcriptase inhibitor (NNRTI). Initially, the NRTI backbone in Khayelitsha comprised zidovudine and lamivudine, but was later changed to stavudine and lamivudine in line with the national programme. Paediatric regimens varied, with NNRTIs and protease inhibitors

Fig. 2. Trends in total patients on ART



ART, antiretroviral therapy.

Fig. 3. A tiered routine monitoring system for ART



ART, antiretroviral therapy.

being variously used with the NRTI backbone.

Six-monthly CD4 counts and viral-load testing were provided in the programme, together with safety monitoring according to the specific regimens. The protocol for changing to second-line therapy was two consecutive viral loads above 5000 copies/ml.<sup>7</sup> All laboratory tests were conducted by the National Health Laboratory Services. CD4 counts were performed using the panLeucogating method.<sup>11</sup> Viral loads were conducted using the NucliSens HIV-1 QT<sup>®</sup> assay, and later NucliSens EasyQ<sup>®</sup> HIV-1 assay (bioMérieux, Boxtel, the Netherlands) for which the upper limit of detection is just under 400 copies/ml, hence the use of 400 copies/ml as the definition of suppression in all registers and analyses.

## Data collection and analysis

### The routine monitoring system

Data analysed were collected through the routine monitoring system. This system is one component of a framework for the monitoring of the ART programme in the province (Fig. 3). Other components include observational cohort studies in sentinel sites, special studies to address priority clinical

research questions, and a passive-stimulated pharmacovigilance reporting system.

Patients are entered into a register in the order in which they start ART. Monthly reporting is universal across the sites and comprises cross-sectional patient and enrolment totals (Fig. 1 and Fig. 2), the essential information required by managers to keep track of resource allocation and progress against targets. Quarterly cohort reports are also universal and are provided a quarter in arrears to allow sites to complete the ascertainment of outcomes before reporting. These reports are aggregated by starting quarter, as well as by 6-monthly durations on ART, allowing for cohort outcomes to be reported. The metrics reported on quarterly include regimen (first- or second-line), CD4 count, viral load and outcome (i.e. in care, transferred out, lost to follow-up, died).

When aggregating from the registers, the measure of advanced immune suppression at baseline is determined by the proportion of adults with a baseline CD4 cell count of less than 50 cells/ $\mu$ l and in children a CD4 percentage of less than 15% of total lymphocytes. Immunological response during follow-up is determined by the proportion of patients tested with CD4

cell counts above 200 cells/ $\mu$ l or greater (20% in children) and virological response by the proportion of patients tested with viral loads below 400 copies/ml. All cohort analyses are limited to treatment-naive patients.

### Data analysis

The monthly data are presented as cross-sectional monthly totals, whilst the quarterly data are presented as combined annual enrolment cohorts followed up until study closure. The monthly data cover April 2004 to March 2006, whilst the cohort data include patients enrolled between May 2001 and December 2005, followed until March 2006. Owing to the aggregate nature of the data, all data are presented as proportions with 95% binomial confidence intervals. The definition of “remaining in care” is patients who had had at least one visit in the preceding 90 days. Correspondingly, the definition of “loss to follow-up” is patients who had not had a contact with the health services for 90 days or more. The small number of patients who transferred their care to other sites are excluded in both the numerator and the denominator in the calculation of the proportions remaining in care, died and lost to follow-up. These measures

Table 1. Estimates of retention in care for treatment-naïve adults

Duration on ART (months)	0	6	12	18	24	30	36	42	48
Total adults starting ART	12 587	8 341	4 726	2 167	852	561	328	189	80
Started before		30 Jun 2005	31 Dec 2004	30 Jun 2004	31 Dec 2003	30 Jun 2003	31 Dec 2002	30 Jun 2002	31 Dec 2001
Deaths since start <sup>a,b</sup>		545 (6.7)	397 (8.8)	239 (11.6)	131 (15.8)	96 (17.6)	60 (18.9)	36 (19.7)	18 (23.1)
Lost to follow-up since start <sup>b,c</sup>		340 (4.2)	286 (6.3)	148 (7.2)	27 (3.3)	18 (3.3)	13 (4.1)	5 (2.7)	1 (1.3)
Transfers out since start <sup>b,d</sup>		223 (2.7)	214 (4.5)	98 (4.5)	23 (2.7)	16 (2.9)	10 (3.0)	6 (3.2)	2 (2.5)
Remaining in care – absolute <sup>e,f</sup>		89.1 (88.4–89.8)	84.9 (83.8–85.9)	81.3 (79.5–83.0)	80.9 (78.1–83.6)	79.1 (75.4–82.4)	77.0 (72.0–81.6)	77.6 (70.9–83.4)	75.6 (64.6–84.7)
Remaining in care – cumulative <sup>g,h</sup>		89.5 (88.9–90.1)	85.3 (84.5–86.1)	82.1 (80.9–83.1)	80.0 (78.5–81.4)	77.8 (75.9–79.6)	74.8 (72.1–77.2)	73.2 (70.0–76.1)	72.0 (68.0–75.6)

ART, antiretroviral therapy.

<sup>a</sup> Deaths since start = deaths / (total - transfers out).

<sup>b</sup> Values in parentheses are percentages.

<sup>c</sup> Lost to follow-up since start = losses to follow-up / (total - transfers out).

<sup>d</sup> Transfers out since start = transfers out / total.

<sup>e</sup> Remaining in care – absolute = (total - losses to follow-up - deaths - transfers out) / (total - transfers out).

<sup>f</sup> Values in parentheses are exact binomial confidence intervals.

<sup>g</sup> Weighted Kaplan–Meier estimate.

<sup>h</sup> Values in parentheses are Greenwood point-wise confidence intervals.

are limited to those patients followed up for at least the full duration under analysis. In addition, the proportion of patients remaining in care is further described as Kaplan–Meier estimates based on weighted survival data derived from the count data. All analyses were performed using Stata statistical software version 9.0 (StataCorp. LP, College Station, TX, United States of America).

## Results


Overall, 12 587 adults and 1709 children were included in this cohort report, totalling 14 296 treatment-naïve patients. This is a near-complete representation of all public-sector patients started on ART in the Western Cape Province by the end of 2005. Follow-up for the oldest quarterly cohorts extends to 4 years on treatment. A further

2.4% of patients were treatment experienced before starting ART, and were not included in this analysis.

The percentage of men starting ART has remained around 30% over the 5 years of enrolment in the province, with a very slight increase over time. The gender breakdown of children is not routinely recorded but reviews of paediatric sentinel site data reveal that the gender breakdown of children starting ART is roughly even. Overall, 22.7% of adults began ART with a CD4 count below 50 cells/ $\mu$ l while 45% of children started ART with a CD4 count below 15% of total lymphocytes.

After 4 years on ART, 76% of adults remained in care (Fig. 4 and Table 1). For each duration on ART, this absolute estimate was based only on the data for those patients who started that number of months previously. Using the weighted survival data, the Kaplan–Meier estimate of retention in care was 72.0% at 4 years on ART with a narrower confidence interval (95% confidence interval, CI: 68.0–75.6). A similar analysis of paediatric outcomes (Fig. 5 and Table 2) revealed 81.5% (95% CI: 75.7–86.1) of

Fig. 4. Estimates of retention in care for treatment-naïve adults



ART, antiretroviral therapy.

Table 2. Estimates of retention in care for treatment-naïve children

Duaction on ART (months)	0	6	12	18	24	30	36
Total children starting ART	1 709	1 216	770	371	72	51	35
Started before		30 Jun 2005	31 Dec 2004	30 Jun 2004	31 Dec 2003	30 Jun 2003	31 Dec 2002
Deaths since start <sup>a,b</sup>		84 (7.4)	68 (9.8)	32 (9.3)	4 (5.7)	4 (8.2)	4 (11.8)
Lost to follow-up since start <sup>b,c</sup>		22 (1.9)	23 (3.3)	19 (5.5)	4 (5.7)	3 (6.1)	2 (5.9)
Transfers out since start <sup>b,d</sup>		84 (6.9)	77 (10.0)	27 (7.3)	2 (2.8)	2 (3.9)	1 (2.9)
Remaining in care – absolute <sup>e,f</sup>		90.6 (88.8–92.3)	86.9 (84.1–89.3)	85.2 (81.0–88.8)	88.6 (78.7–94.9)	85.7 (72.8–94.1)	82.4 (65.5–93.2)
Remaining in care – cumulative <sup>g,h</sup>		90.9 (89.3–92.4)	88.5 (86.5–90.2)	84.8 (81.9–87.2)	83.5 (79.4–86.8)	81.5 (75.7–86.1)	81.5 (75.7–86.1)

ART, antiretroviral therapy.

<sup>a</sup> Deaths since start = deaths / (total - transfers out).

<sup>b</sup> Values in parentheses are percentages.

<sup>c</sup> Lost to follow-up since start = losses to follow-up / (total - transfers out).

<sup>d</sup> Transfers out since start = transfers out / total.

<sup>e</sup> Remaining in care = (total - losses to follow-up - deaths - transfers out) / (total - transfers out).

<sup>f</sup> Values in parentheses are exact binomial confidence intervals.

<sup>g</sup> Weighted Kaplan–Meier estimate.

<sup>h</sup> Values in parentheses are Greenwood point-wise confidence intervals.

children remained in care after 3 years. If looking only at those children who had been in care for the entire 3 years, the estimate is comparable (82.4%). In both adults and children starting ART, mortality was highest in the first 6 months on therapy.

The first laboratory metric reported on is the proportion of tests that are done when they should be done. This is a proxy for quality of care. Results were received in the cohort system for four out of five patients who should have received these tests (Table 3). There is currently a slight drop-off in the test completion proportion as the duration on ART increases.

Looking at adult laboratory outcomes, of those tested, 90.6% of adults achieved virological suppression by 6 months on ART (Table 3). Although the proportion of patients on second-line regimens increases with duration on ART, and the data system does not distinguish which viral loads are done in patients on first-line versus those on second-line, for all patients combined this percentage remained at 85% or above until 4 years on ART. At 2 years on ART, 3.7% of adults were on second-line, rising to 17.9% at 4 years on ART. Combining all adult patients together, irrespective of the duration on ART, 1.3% of patients were


reported to be on second-line regimens at the end of 2005. At the end of the first year on treatment, 74.7% of adult patients had attained a CD4 count above 200 cells/μl or greater, rising to 86.0% at 2 years on ART and 95.3% at 4 years on ART.

The proportion of children achieving virological suppression ranged between 70% and 80% during the 3 years' duration of follow-up (Table 3), while 7.4% had been changed to second-line by 3 years on ART. By 2 years on ART,

85.7% of children had achieved a CD4 greater than 20% of lymphocytes.

As the rate of enrolment increased in the province (Fig. 1 and Fig. 2), the severity of illness in patients starting ART decreased, evidenced by the lower proportion with CD4 cell counts below 50 cells/μl at ART initiation. In 2001 and 2002, half the adult patients starting ART had a CD4 count below 50 cells/μl, whereas this fell to 21.5% in 2005. This, coupled with the expansion of the programme into different

Fig. 5. Estimates of retention in care for treatment-naïve children



ART, antiretroviral therapy.

Table 3. Laboratory outcomes in treatment-naive adults and children on ART

Duration on ART (months)	6	12	18	24	30	36	42	48
<b>Adults in care and on ART</b>	7 100	3 738	1 640	651	414	237	139	56
<b>On second-line (%)</b>	0.5	1.8	3.3	3.7	4.8	9.7	10.8	17.9
<b>Viral loads done</b>	5 979	3 330	1 401	573	343	171	93	44
Completion (%)	84.2	89.1	85.4	88.0	82.9	72.2	66.9	78.6
< 400 copies/ml (%)	90.6	89.0	88.1	88.3	88.0	86.0	84.9	90.9
95% CI	89.8–91.3	87.9–90.0	86.3–89.7	85.4–90.8	84.1–91.3	79.8–90.8	76.0–91.5	78.3–97.5
<b>CD4 counts done</b>	5 972	3 335	1 380	564	331	168	95	43
Completion (%)	84.1	89.2	84.1	86.6	80.0	70.9	68.3	76.8
≥ 200 cells/μl (%)	62.2	74.7	82.0	86.0	90.9	88.1	88.4	95.3
95% CI	60.9–63.4	73.2–76.2	79.9–84.0	82.9–88.8	87.3–93.8	82.2–92.6	80.2–94.1	84.2–99.4
<b>Children in care and on ART</b>	1 019	597	293	62	41	27	–	–
<b>On second-line (%)</b>	0.1	0.7	2.0	4.8	4.9	7.4	–	–
<b>Viral loads done</b>	822	531	245	53	28	20	–	–
Completion (%)	80.7	88.9	83.6	85.5	68.3	74.1	–	–
< 400 copies/ml (%)	72.7	72.3	74.7	77.4	78.6	75.0	–	–
95% CI	69.6–75.8	68.3–76.1	68.8–80.0	63.8–87.7	59.0–91.7	50.9–91.3	–	–
<b>CD4 counts done</b>	807	499	219	35	17	6	–	–
Completion (%)	79.2	83.6	74.7	56.5	41.5	22.2	–	–
> 20% lymphocytes (%)	57.5	71.5	74.9	85.7	88.2	83.3	–	–
95% CI	54.0–60.9	67.4–75.5	68.6–80.5	69.7–95.2	63.6–98.5	35.9–99.6	–	–

ART, antiretroviral therapy; CI, confidence interval.

communities, has seen mortality during the first 6 months on ART almost halved from 12.7% to 6.6% (Fig. 6 and Table 4). At the same time there has been an increase in the proportion of patients lost to follow-up. For patients starting ART in 2005, 4.7% had been lost to follow-up 6 months after starting ART.

## Discussion

This analysis, based on routine data from a paper-based monitoring system, has demonstrated good cohort retention at 4 and 3 years in adults and children respectively, combined with favourable immunological and virological responses to therapy. As fewer patients have over time started ART with very low CD4 counts, so too has the mortality in the first 6 months of treatment declined.

The antiretroviral services in the Western Cape Province are representative of the national programme in South Africa, with the prior experience of innovator sites providing the oppor-

tunity to anticipate clinical outcomes and challenges that will be faced in the national programme.

The accumulated experience of these sites enabled the province to rapidly scale-up treatment in terms of both sites and patients around the time that the national programme became a reality. It is estimated that, in the final year under review in this paper, half of those newly in need of antiretroviral therapy were able to access it in the province. The falling proportion of adult patients with extremely low CD4 counts at enrolment reflects the impact of this scaling-up of ART provision.

The concurrent halving in early mortality at 6 months on ART, which accompanied the improved immunological status of adults starting ART, suggests that the high early mortality that is characteristic of programmes in the region is in part mediated by the extreme disease advancement at enrolment. This concurs with studies that have been able to stratify outcomes based on CD4 count categories.<sup>2,5,12,13</sup>

Measures of the baseline CD4 count on enrolment may prove to be an extremely useful barometer of the extent to which programmes have caught up with the backlog in treatment in instances where the need for ART cannot be easily assessed.

A key limitation of this analysis, and all analyses of aggregate data, is the inability to stratify outcomes by individual baseline measures of disease severity. It is not possible from this analysis to determine if the decline over time in early mortality is fully mediated by measured improvements in the baseline clinical status of patients starting therapy.


Increasingly, patients lost to follow-up are outnumbering patients who are known to have died in developing country cohorts.<sup>14</sup> For this reason we believe that retention in care is the most useful metric for reporting on programme effectiveness. Retention in care in this analysis at 3 and 4 years on ART demonstrates unequivocally the huge survival benefit conferred by

the intervention. Most of the current simulation models that anticipate either patient numbers or the costs associated with ART have assumed a median of between 6 and 7 years survival on ART.<sup>15</sup> The current data at 4 years, where 7 out of 10 adult patients are still in care, suggest that these estimates are not overoptimistic, especially since many of the patients lost to care may well subsequently return to care, given the very tight definition of loss to follow-up.

Using 90 days without a clinical visit as the definition of loss to follow-up enables programmes to rapidly identify changes in this parameter and respond appropriately. It also fits in very well with the quarterly cohort reporting ensuring that, when reporting one quarter in arrears, all outcomes can be fully ascertained. On the other hand, many analyses have used longer durations (up to 1 year) without contact with the services to define loss to follow-up.<sup>13</sup>

Notwithstanding the definition used, a higher proportion of patients were lost to follow-up in the first 6 months on ART in 2005 compared to previously. It is probable that clinic patient loads exceeding manageable numbers in some clinics are affecting this. It is clear that retaining patients in constant care will become increasingly difficult as the service continues to expand, highlighting the importance of adherence promotion extending beyond the health services to the national and local media, political, social and religious platforms, as well as through community interventions. Decentralization of care to more facilities, and the appropriate resourcing of services, are key to ensuring that services at indi-

Fig. 6. Temporal trends in baseline CD4 count survival and loss to follow-up at 6 months in adults starting ART



ART, antiretroviral therapy.

vidual facilities remain of a manageable size and are able to appropriately retain patients in care.

Even though most services retained some capacity to actively follow up patients lost to care during the period under review, it is probable that there remains residual under-ascertainment of mortality in the latter years as loss to follow-up increased.<sup>16</sup> It is further unknown to what extent in future the increased loss to follow-up will result in intermittent care and consequently increased virological resistance due to repeated treatment interruptions (which are known to be strongly associated with resistance).<sup>17</sup>

The slower increase over time in the numbers of children on ART compared to adults is entirely anticipated and does not imply that children are being underprovided for. Whereas the number of adults newly needing ART increases year on year, the number

of children is decreasing due to successful implementation of a prevention of mother-to-child transmission programme.<sup>18,19</sup>

The virological outcomes are encouraging and suggest that at a population level the rates of viral rebound have not been alarming and are not undermining overall programme success. Nevertheless, with up to one in five patients requiring second-line therapy by 5 years on ART, it is clear that the higher cost of second-line drugs will impact on total programme costs as programmes mature.<sup>20</sup>

There have been many lessons learned in implementing the WHO monitoring approach. This system, based on registers and regular cohort analyses, shares many attributes with systems that have been in use for many years for monitoring tuberculosis programmes. Worth noting is the value of differentiating sentinel from routine

Table 4. Temporal trends in baseline CD4 count survival and loss to follow-up at 6 months in adults starting ART

Number of adults <sup>a</sup>	80	248	524	3981	3508
Year started on ART	2001	2002	2003	2004	2005
CD4 < 50 cells/ $\mu$ l <sup>b,c</sup>	51.3 (39.8–62.6)	50.4 (44.0–56.8)	36.8 (32.7–41.1)	24.4 (23.1–25.8)	21.5 (18.8–20.6)
Mortality <sup>c,d</sup>	12.7 (6.2–21.8)	11.7 (8.0–16.4)	9.6 (7.2–12.4)	6.0 (5.1–6.6)	6.6 (5.6–7.3)
Loss to follow-up <sup>c,e</sup>	0.0 (0.0–4.5)	0.4 (0.0–2.2)	1.7 (0.8–3.2)	4.4 (3.7–4.9)	4.7 (3.9–5.3)

ART, antiretroviral therapy; CI, confidence interval.

<sup>a</sup> Number starting in year and reaching 6 months of follow-up.

<sup>b</sup> Proportion in starting cohort with CD4 counts < 50 cells/ $\mu$ l.

<sup>c</sup> Values in parentheses are exact binomial confidence intervals.

<sup>d</sup> Mortality = deaths by 6 months / (total in cohort - transfers out by 6-months).

<sup>e</sup> Loss to follow-up = losses to follow-up by 6 months / (total in cohort - transfers out by 6 months).

Andrew Boulle et al.

sites,<sup>21</sup> liberating the majority of sites from onerous data-collection procedures that are designed for clinical research rather than for supporting routine care. It has been our experience that, with viral loads being available, managers have paid little attention to CD4 count outcomes in assessing programme performance. We have also found that presenting the completion proportions for laboratory outcomes is an invaluable metric over and above the outcomes themselves in the subset of patients for whom results are available. Finally, one of the major challenges emerging as models of care evolve is the large number of patients moving between facilities, who, once transferred out, are censored in the cohort analyses.

The ability to report on cohort outcomes without electronic systems underscores the value of implementing a basics-first approach to routine monitoring. This does not mean that there is no role for the progressive and measured development of electronic

systems<sup>22</sup> but rather that the basic building blocks that are required for a paper-based system are the same measures that will make electronic systems a success.<sup>23</sup>

Perhaps the most important lesson from the first 5 years of this programme is that implementing an ART programme in primary-care facilities from the outset is feasible and can achieve excellent clinical results. It is probable that the location of care in community clinics is one of the key factors contributing to the retention of patients in care.<sup>24</sup>

Looking to the future, if the Western Cape Province is to come close to the stated target of treating 80% of patients newly in need of therapy each year over the coming years, the annual number of patients enrolling in care will need to double while the total number of patients in care quadruples over a 5-year period. This will require even further task-shifting and expansion of the service platform, given that enrolment is already threatened by

capacity constraints in the existing service platform.<sup>25</sup>

In conclusion, this paper has demonstrated excellent clinical outcomes 5 years after the Western Cape Province began offering ART in the public sector, validating the decision to make this a primary-care intervention from the outset. The WHO monitoring system has enabled the province to keep track of the intervention and of the performance of individual sites, while allowing space for more complex and durable solutions to be developed for the larger sites. ■

**Funding:** The following organizations have provided support in whole or in part to various of the authors during the study period: the Provincial Government of the Western Cape; Médecins Sans Frontières; the Global Fund to fight AIDS Tuberculosis and Malaria; NIH grant U01 AI069924-01.

**Competing interests:** None declared.

## Résumé

### Traitement antirétroviral et mortalité précoce en Afrique du Sud

**Objectif** Décrire les résultats à l'échelle provinciale et les tendances dans le temps du programme de traitement antirétroviral (ART) de la province du Cap-Occidental, 5 ans après son lancement et démontrer l'utilité du système de surveillance de l'OMS pour ce traitement.

**Méthodes** Le programme de traitement a débuté en 2001 au niveau de sites « novateurs ». Un rapide passage à l'échelle supérieure de la délivrance du traitement a commencé début 2004, à partir essentiellement d'établissement de soins de santé primaire. Des données relatives aux patients entamant un traitement ART ont été recueillies de manière prospective dans les registres des établissements de soins, ce qui a permis de constituer des rapports mensuels d'activité et des rapports trimestriels de cohorte. Les taux de rétention sous traitement et de mortalité, ainsi que les nombres de perdus pour le suivi et les résultats de laboratoire ont été calculés tous les 6 mois sous ART.

**Résultats** Fin mars 2006, 16 234 patients étaient sous

traitement. L'analyse de cohorte a porté sur 12 587 adultes et 1709 enfants. Les femmes représentaient 70 % des adultes inclus dans l'étude. Après 4 et 3 ans sous traitement ART, respectivement 72,0 % des adultes (intervalle de confiance à 95 % : 68,0-75,6) et 81,5 % des enfants (IC à 95 % : 75,7-86,1) étaient encore sous traitement. Le pourcentage des adultes débutant le traitement ART avec une numération des CD4 inférieure à 50 cellules/ $\mu$ l est tombé de 51,3 % en 2001 à 21,5 % en 2005, tandis que la mortalité à 6 mois passait de 12,7 % à 6,6 %, baisse en partie compensée par l'augmentation du nombre de perdus pour le suivi (atteignant 4,7 % à 6 mois en 2005). Plus de 85 % des adultes dépistés présentaient une charge virale inférieure à 400 copies/ml tous les 6 mois jusqu'à 4 ans sous ART.

**Conclusion** La dispensation par ce programme des soins dans des sites de soins de santé primaire était associée à un taux de rétention satisfaisant, tandis que l'élargissement du programme était associé à une réduction de la mortalité précoce.

## Resumen

### Tratamiento antirretroviral y mortalidad temprana en Sudáfrica

**Objetivo** Describir los resultados y las tendencias temporales a escala provincial del programa de tratamiento antirretroviral (TAR) de la Provincia de El Cabo Occidental a los 5 años de su puesta en marcha y demostrar la utilidad del sistema de vigilancia de la OMS para el TAR.

**Métodos** El programa de tratamiento dio comienzo en 2001 a partir de establecimientos innovadores. La rápida expansión del suministro de TAR comenzó a principios de 2004 y se centró predominantemente en los servicios de atención primaria. Los datos sobre los pacientes que comenzaron el TAR se reunieron de forma



prospectiva en los registros de los centros, a partir de los cuales se elaboraron informes mensuales transversales de actividad e informes trimestrales de cohortes. La retención en el sistema de atención, la mortalidad, las pérdidas para el seguimiento y las variables de laboratorio se calcularon considerando los periodos de 6 meses de TAR.

**Resultados** Al final de marzo de 2006 se estaba tratando a 16 234 pacientes. El análisis de cohortes abarcó a 12 587 adultos y 1709 niños. Las mujeres representaban el 70% de todos los adultos estudiados. Al cabo de 4 y 3 años de TAR, respectivamente, el 72,0% de los adultos (intervalo de confianza del 95%, IC95%: 68,0–75,6) y el 81,5% (IC95%: 75,7–86,1)

de los niños seguían atendidos. El porcentaje de adultos que comenzaron el TAR con recuentos de CD4 inferiores a 50 células/ $\mu$ l cayó del 51,3% en 2001 al 21,5% en 2005, mientras que la mortalidad a 6 meses cayó del 12,7% al 6,6%, compensada en parte por un aumento de las pérdidas para el seguimiento (que alcanzó el 4,7% a los 6 meses en 2005). Más del 85% de los adultos analizados presentaron cargas virales inferiores a 400 copias/ml a intervalos de 6 meses durante los 4 años de TAR.

**Conclusión** La ubicación de la asistencia en los centros de atención primaria en este programa se asoció a una buena retención de los pacientes, mientras que la expansión del TAR se asoció a una disminución de la mortalidad temprana.

## ملخص

### المعالجة بمضادات الفيروسات القهقرية والوفيات المبكرة في جنوب أفريقيا

95%، إذ تراوح معدل الأرجحية بين 68.0 و75.6)، وبعد 3 سنوات كانت نسبة الاستمرار تحت الرعاية بالنسبة للأطفال الذين يتلقون المعالجة بمضادات الفيروسات القهقرية 81.5% (بفاصل ثقة 95%، إذ تراوح معدل الأرجحية بين 75.7 و86.1). فنسبة البالغين الذين بدأوا المعالجة بمضادات الفيروسات القهقرية وكان عدد CD4 لديهم أقل من 50 خلية لكل مكروتر، انخفضت من 51.3% في عام 2001 إلى 21.5% في عام 2005، في حين انخفضت الوفيات خلال 6 شهور من 12.7% إلى 6.6%. ولكن هذه النتيجة تكافأت جزئياً مع زيادة عدد من فقدوا وتسربوا من المتابعة (لتصل إلى 4.7% في خلال 6 شهور من عام 2005). فأكثر من 85% من البالغين الذين تم اختبارهم كان عبء الفيروس لديهم أقل من 400 نسخة لكل ملي لتر على مدى 6 شهور من المعالجة بمضادات الفيروسات وحتى مرور أربع سنوات من استمرار المعالجة بمضادات الفيروسات القهقرية.

**الاستنتاج:** إن وضع الرعاية في مواقع الرعاية الأولية في هذا البرنامج يصاحبه معدلات جيدة لاستبقاء المرضى في الرعاية، وفي الوقت نفسه فإن الارتقاء بتقديم المعالجة الدوائية بمضادات الفيروسات القهقرية يصاحبه تقلص الوفيات المبكرة.

**الهدف:** توضيح النتائج على مستوى المقاطعة، والاتجاهات الزمنية لبرنامج المعالجة بالأدوية المضادة للفيروسات القهقرية في مقاطعة الرأس الغربي بعد مضي خمس سنوات من إدخال البرنامج، وإبراز جدوى نظام المنظمة الخاص برصد المعالجة بمضادات الفيروسات القهقرية.

**الطريقة:** بدأ برنامج المعالجة في عام 2001 من خلال مواقع مستحدثة. كما بدأ تسريع وتيرة الارتقاء بتقديم المعالجة بمضادات الفيروسات القهقرية في مطلع عام 2004، في مرافق الرعاية الأولية بشكل أساسي. وتم تسجيل المؤشرات الخاصة بالمرضى الذين بدءوا في تلقي المعالجة بمضادات الفيروسات القهقرية في سجلات المرافق، مما ساعد على تجميع التقارير الأثرية ربع السنوية، والنشاط الشهري. وتم احتساب معدلات استبقاء المرضى تحت الرعاية، والوفيات، والفقدان أو التسرب من المتابعة، والنتائج المختبرية كل ستة أشهر من المعالجة بمضادات الفيروسات القهقرية.

**الموجودات:** بنهاية آذار/مارس 2006، وجد أن عدد المرضى تحت الرعاية يبلغ 16 234 مريضاً. فقد تضمن التحليل الأثري 12 587 بالغاً، و1709 من الأطفال، بينما مثلت النساء 70% من البالغين المدرجين بالتحليل. وبعد مضي أربع سنوات كانت نسبة الاستمرار في تلقي الرعاية بين من يتلقون المعالجة بمضادات الفيروسات القهقرية من البالغين 72.0% (بفاصل ثقة

## References

1. *Operational plan for comprehensive HIV and AIDS care, management and treatment for South Africa*. Pretoria: National Department of Health; 2003. Available from: <http://www.info.gov.za/issues/hiv/careplan.htm> [accessed on 16 October 2007].
2. Coetzee D, Hildebrand K, Boule A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. *AIDS* 2004;18:887-95. PMID:15060436 doi:10.1097/00002030-200404090-00006
3. Coetzee D, Boule A, Hildebrand K, Asselman V, Van CG, Goemaere E. Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. *AIDS* 2004;18 Suppl 3:S27-31. PMID:15322481 doi:10.1097/00002030-200406003-00006
4. Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. *S Afr Med J* 2006;96:315-20. PMID:16670804
5. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. *AIDS* 2005;19:2141-8. PMID:16284464
6. Orrell C, Harling G, Lawn S, Kaplan R, McNally M, Bekker LG, et al. Conservation of first line antiretroviral treatment regimen where therapeutic options are limited. *Antivir Ther* 2007;12:83-8. PMID:17503751
7. *Antiretroviral treatment protocol* [version 2]. Cape Town: Provincial Government of the Western Cape; 2004. Available from: <http://web.uct.ac.za/depts/epi/artrollout/> [accessed on 16 October 2007].
8. *Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access*. Geneva: WHO; 2006. Available from: <http://www.who.int/hiv/pub/guidelines/adult/en/index.html> [accessed on 16 October 2007].
9. South African national antiretroviral treatment guidelines, 1st edn. Pretoria: National Department of Health; 2004. Available from: <http://www.doh.gov.za/docs/factsheets/guidelines/artguidelines04/intro.pdf> [accessed on 16 October 2007].
10. *Patient monitoring guidelines for HIV care and antiretroviral therapy (ART)*. Geneva: WHO; 2006. Available from: <http://www.who.int/3by5/capacity/ptmnguidelinesfinalv1.PDF> [accessed on 16 October 2007].
11. Glencross D, Scott LE, Jani IV, Barnett D, Janosy G. CD45-assisted PanLeucogating for accurate, cost-effective dual-platform CD4+ T-cell enumeration. *Cytometry* 2002;50:69-77. PMID:12116348 doi:10.1002/cyto.10068
12. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. *JAMA* 2006;296:782-93. PMID:16905784 doi:10.1001/jama.296.7.782

13. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. *Lancet* 2006;367:817-24. PMID:16530575 doi:10.1016/S0140-6736(06)68337-2
14. Rosen S, Fox P, Gill C. Patient retention in antiretroviral therapy programs in Sub-Saharan Africa: a systematic review. *PLoS Med* 2007;4:1-11. doi:10.1371/journal.pmed.0040001
15. Boulle A, Kenyon C, Abdullah F, Moatti JP, Coriat B, Souteyrand Y, et al. A review of antiretroviral costing models in South Africa. *Economics of AIDS and access to HIV/AIDS care in developing countries. Issues and challenges*. Paris: ANRS; 2003 pp. 293-310.
16. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. *Bull World Health Organ* 2007;85:550-4. PMID:17768504
17. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. *AIDS* 2007;21:965-71. PMID:17457090 doi:10.1097/QAD.0b013e32802e6bfa
18. Abdullah MF, Young T, Bitalo L, Coetzee N, Myers JE. Public health lessons from a pilot programme to reduce mother-to-child transmission of HIV-1 in Khayelitsha. *S Afr Med J* 2001;91:579-83. PMID:11544974
19. Coetzee D, Hilderbrand K, Boulle A, Draper B, Abdullah F, Goemaere E. Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa. *Bull World Health Organ* 2005;83:489-94. PMID:16175822
20. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa – a primary data analysis. *Cost Eff Resour Alloc* 2006;4:20. PMID:17147833 doi:10.1186/1478-7547-4-20
21. *The Western Cape Antiretroviral Programme: monitoring report*. Cape Town: Provincial Government of the Western Cape; 2006. Available from: [http://web.uct.ac.za/depts/epi/artrollout/files/Artmonitoringreport\\_wc\\_062006.pdf](http://web.uct.ac.za/depts/epi/artrollout/files/Artmonitoringreport_wc_062006.pdf) [accessed on 16 October 2007].
22. Tierney WM, Beck EJ, Gardner RM, Musick B, Shields M, Shiyonga NM, et al. Viewpoint: a pragmatic approach to constructing a minimum data set for care of patients with HIV in developing countries. *J Am Med Inform Assoc* 2006;13:253-60. PMID:16501175 doi:10.1197/jamia.M2005
23. Harries AD, Gomani P, Teck R, de Teck OA, Bakali E, Zachariah R, et al. Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model. *Trans R Soc Trop Med Hyg* 2004;98:695-701. PMID:15485699 doi:10.1016/j.trstmh.2004.05.002
24. Pienaar D, Myer L, Cleary S, Coetzee D, Michaels D, Cloete K, et al. *Models of care for antiretroviral service delivery*. Cape Town: University of Cape Town; 2006. Available from: <http://web.uct.ac.za/depts/epi/artrollout/> [accessed on 16 October 2007].
25. Boulle AM, Coetzee DJ. Anticipating future challenges to ART provision in South Africa: reflections on the Khayelitsha ART programme. *Acta Academic – University of the Free State* 2006; Suppl 1;241-55.